Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn’s Disease: Correlations Between Disease Activity and Long-Term Follow-Up

Jones, G. R.; Fascì-Spurio, Federica; Kennedy, Nicholas A.; Plevris, Nikolas; Jenkinson, P; Lyons, Mathew; Wong, L; MacLean, P; Glancy, Stephen; Lees, Charlie W

doi:10.1093/ecco-jcc/jjy187

Cited by 23 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Además, la CF en concentraciones elevadas a pesar de la remisión clínica también se ha detectado en varios estudios tanto en adultos como en niños, mientras que una concentración baja de CF predice la persistencia de la remisión clínica. Así mismo, se ha descrito que los pacientes que requerían colectomía presentaban una concentración de CF significativamente más alta que aquellos que no la necesitaban 45,46 . Finalmente, en las guías clínicas internacionales se recomienda que la prueba de CF sea obligatoria no solo en el diagnóstico, sino también en la evolución de la enfermedad, así como en el seguimiento terapéutico 47,48 .…”

Section: La Calprotectina Fecal En La Fase De Remisión Y Como Predictor De Recaída En La Enfermedad Inflamatoria Intestinalunclassified

Importancia de la prueba de calprotectina fecal en la enfermedad inflamatoria intestinal

Maldonado-Arriaga¹

2023

IMIDS

View full text Add to dashboard Cite

La enfermedad inflamatoria intestinal (EII) es un problema sanitario mundial con una incidencia en aumento continuo. Se caracteriza por una inflamación intestinal crónica e incluye dos condiciones clínicas: la enfermedad de Crohn y la colitis ulcerativa. Hasta hace poco, el diagnóstico se basaba principalmente en criterios clínicos y endoscópicos, por lo que ha existido la necesidad de utilizar una prueba no invasiva para el diagnóstico, el pronóstico y el seguimiento de la EII. Hasta la fecha, la calprotectina fecal (CF) es la prueba más estudiada y la que mejores resultados ha mostrado. La calprotectina es una proteína de unión al zinc y al calcio de 36 kDa que es expresada principalmente por los neutrófilos. La concentración de CF aumenta debido a la agregación de neutrófilos en la mucosa del intestino inflamado; por tanto, es útil como marcador no invasivo

show abstract

Section: La Calprotectina Fecal En La Fase De Remisión Y Como Predictor De Recaída En La Enfermedad Inflamatoria Intestinalunclassified

Importancia de la prueba de calprotectina fecal en la enfermedad inflamatoria intestinal

Maldonado-Arriaga¹

2023

IMIDS

View full text Add to dashboard Cite

show abstract

“…Calprotectin, formed as a heterodimer of S100A8 and S100A9, constitutes about 60% of soluble cytosol proteins in human neutrophil granulocytes . Calprotectin is released by granulocyte activation and elevated level of fecal calprotectin (FC) is found in the GI tract inflammation that closely related to inflammatory bowel disease (IBD) activity . Increasing evidence indicates that FC can be used as a noninvasive marker for intestinal/colonic inflammation that helps clinicians distinguish organic inflammatory bowel disease (IBD) from functional irritable bowel syndrome (IBS) .…”

Section: Introductionmentioning

confidence: 99%

“…Increasing evidence indicates that FC can be used as a noninvasive marker for intestinal/colonic inflammation that helps clinicians distinguish organic inflammatory bowel disease (IBD) from functional irritable bowel syndrome (IBS) . Markers of systemic inflammation, such as C‐reactive protein (CRP) and white blood cells count, have low specificity and sensitivity for IBD, while the gold standard of ileo‐colonoscopy is invasive and expensive . Thus, noninvasive method for monitoring disease activity is preferable.…”

Section: Introductionmentioning

confidence: 99%

“…1 Calprotectin is released by granulocyte activation and elevated level of fecal calprotectin (FC) is found in the GI tract inflammation that closely related to inflammatory bowel disease (IBD) activity. 2,3 Increasing evidence indicates that FC can be used as a noninvasive marker for intestinal/colonic inflammation that helps clinicians distinguish organic inflammatory bowel disease (IBD) from functional irritable bowel syndrome (IBS). [4][5][6] Markers of systemic inflammation, such as C-reactive protein (CRP) and white blood cells count, have low specificity and sensitivity for IBD, while the gold standard of ileo-colonoscopy is invasive and expensive.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6] Markers of systemic inflammation, such as C-reactive protein (CRP) and white blood cells count, have low specificity and sensitivity for IBD, while the gold standard of ileo-colonoscopy is invasive and expensive. 3 Thus, noninvasive method for monitoring disease activity is preferable. FC is more sensitive than serum CRP in reflecting disease activity in IBD 7 and can be used to identify patients at risk of relapse and predict both endoscopic and histological mucosal healing.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of a fluorescent immunochromatography test for fecal calprotectin

Zhao

Dong

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Fecal calprotectin (FC) is widely used to discriminate between patients with inflammatory diseases such as inflammatory bowel disease (IBD) and functional diseases such as irritable bowel syndrome (IBS). ELISA is a time‐consuming method for the measurement of FC, whereas a fluorescent immunochromatography test can obtain results in around 30 minutes and thus enables a rapid response to clinical decision. Methods Two methods, the Proglead® calprotectin (FC Proglead) and the BÜHLMANN fCAL® ELISA (FC BÜHLMANN), were used to quantitatively examine FC in 111 stool samples. The comparison and bias estimation of both assays were assessed using CLSI EP09c protocol. Results The two methods were highly correlated (rho = .96). Deming regression was employed to calculate the regression equation, with a slope of 1.01 and an intercept of −4.98 μg/g. The estimated median bias (FC Proglead − FC BÜHLMANN) was −4.19 μg/g with the 95% limits of agreement (−55.59 to 47.21 μg/g), and the estimated median percent bias was −8.71% with the 95% limits of agreement (−50.31% to 32.90%). There was 4.50% (5/111) of values outside the 95% limits of agreement. Percent biases at the FC cutoff values of 50 and 200 μg/g between both methods evaluated by Deming regression were 8.96% and 1.49%, respectively. The biases were all less than the acceptable standard (10%). And, 99.10% of FC results were in agreement between both methods (kappa = .99, P < .001). Conclusions FC Proglead may be used as a suitable alternative to FC BÜHLMANN for the disease activity assessment for patients with IBD, considering its convenience and shorter turnaround time.

show abstract

Assessing Active Bowel Inflammation in Crohn's Disease Using Intestinal Ultrasound

You

Moon

Lee

et al. 2023

J of Ultrasound Medicine

View full text Add to dashboard Cite

AimTo analyze the correlation between intestinal ultrasound (IUS) and serum and fecal biomarkers, and the characteristics of small bowel disease, for the assessment of active bowel inflammation.MethodsPatients with Crohn's disease (CD) who underwent an initial IUS examination between July 2018 and November 2022 at our institution were included retrospectively. We divided small and large bowels into seven segments, and recorded the presence of active inflammation according to following criteria: bowel wall thickness ≥ mm with ≥1 of feature of active disease on IUS. The correlations between IUS‐assessed activity and serum C‐reactive protein (CRP, mg/dL) and fecal calprotectin (FC, μg/g) levels were analyzed.ResultsA total of 127 patients were included (mean age: 32.42 ± 12.07, M:F = 90:37, median disease duration 6 years [0–35]). Of them, 78 showed active bowel inflammation (61.4%), with inflammation distal to the terminal ileum being the most common disease location (n = 61, 78.2%). FC and serum CRP levels were significantly correlated with the number of segments with active inflammation (rho = 0.58, 0.48), number of segments with complications (r = 0.35, 0.31), and US activity score (r = 0.62, 0.54). With FC cutoff values of 100 and 150 μg/g, the concordance rates for patients with active small bowel disease were 78.7% (26/33) and 72.7% (24/33), respectively, which were better than those for other disease locations.ConclusionsDisease activity determined by IUS was significantly correlated with the biomarkers, with a better concordance rate in patients with active small bowel disease than in those with other disease locations with FC cut‐off values of 100 and 150 μg/g.

show abstract

Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn’s Disease: Correlations Between Disease Activity and Long-Term Follow-Up

Cited by 23 publications

References 28 publications

Importancia de la prueba de calprotectina fecal en la enfermedad inflamatoria intestinal

Importancia de la prueba de calprotectina fecal en la enfermedad inflamatoria intestinal

Evaluation of a fluorescent immunochromatography test for fecal calprotectin

Assessing Active Bowel Inflammation in Crohn's Disease Using Intestinal Ultrasound

Contact Info

Product

Resources

About